Oppenheimer Maintains Outperform on Sagimet Biosciences, Raises Price Target to $38
Benzinga Newsdesk 1 month ago
Analyst RatingsNewsPrice Target
Oppenheimer analyst Jay Olson maintains Sagimet Biosciences (NASDAQ:SGMT) with a Outperform and raises the price target from $33 to $38.
Oppenheimer analyst Jay Olson maintains Sagimet Biosciences (NASDAQ:SGMT) with a Outperform and raises the price target from $33 to $38.